Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis

Crit Care. 2021 Apr 20;25(1):152. doi: 10.1186/s13054-021-03568-8.

Brendan Le Daré^{1

2}, Christelle Boglione-Kerrien³, Florian Reizine^{4

5}, Jean-Pierre Gangneux⁶, Astrid Bacle^{7

6}

¹ Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes, France. [email protected].
² INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Univ Rennes, Rennes, France. [email protected].
³ Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Rennes University Hospital, 35033, Rennes, France.
⁴ Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033, Rennes, France.
⁵ Faculté de Médecine, Biosit, Université Rennes 1, 35043, Rennes, France.
⁶ Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France.
⁷ Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes, France.

No abstract available

MeSH terms